



## 2024 Top MIPS Proposed Changes

Below is a quick rundown of some major proposed MIPS changes relevant to what we use in our specialties. Most proposed changes would be effective in 2024, unless otherwise specified. Names of measures and activities are abbreviated.

### Overall Top Proposed Changes:

- Avoid the penalty threshold: proposal to increase to 82 pts (up from 75 pts in 2023).
- PI performance period proposed to increase to 180 consecutive days.
- No MVP proposals that impact ophthalmology or dermatology.

### Top Proposed Changes by Category:

<b>Quality (30%)</b>	<ul style="list-style-type: none"> <li>• Changes to existing measures are mostly clarifications or removals.</li> <li>• Data completeness threshold to increase to 75% (up from 70% in 2023).</li> <li>• 2027 data completeness threshold to increase to 80%.</li> </ul>
<b>PI (25%)</b>	<ul style="list-style-type: none"> <li>• Performance period proposed to increase to 180 consecutive days.</li> <li>• Low-volume exclusion for Query of PDMP measure: now only applies to clinicians/groups who do not e-prescribe <i>any</i> Schedule II opioids or Schedule III/IV drugs.</li> <li>• Proposal to require the SAFER Guide High Priority assessment.</li> </ul>
<b>IA (15%)</b>	<ul style="list-style-type: none"> <li>• Five proposed new IAs, none relevant to our specialists.</li> <li>• One change to existing IAs (IA_PSPA_16: Use of Decision Support and Standardized Treatment Protocols).</li> <li>• Three proposed removals, none relevant to our specialists.</li> </ul>
<b>Cost (30%)</b>	<ul style="list-style-type: none"> <li>• No significant changes for our specialists proposed for 2024.</li> </ul>

### Quality Measure Proposed Changes:

#### Ophthalmology

ID	Name	Measure Specific
14	AMD: Dilated Macular Examination	-Removal from MIPS as it is at the end of the topped-out lifecycle.
19	Diabetic Retinopathy: Communication with Managing Physician	-Clarification: the dilated macular or fundus exam must be performed and communicated to the physician managing the patient's diabetes care during the performance year (between Jan 1 and Dec 31).
117	Diabetes Eye Exam	-MIPS CQM denominator exclusion added: Donepezil-memantine to the list of dementia medication exclusions. -MIPS CQM new option for satisfying measure: reporting 92229 (allowing AI screening for diabetic retinopathy).
141	POAG: Reduction of IOP by 15% OR Documentation of Plan of Care	-Title change: POAG: Reduction of IOP by <b>20%</b> OR Documentation of Plan of Care -In order to satisfy the measure, you must now achieve a 20% reduction from pre-intervention IOP (up from 15%) or document a plan of care.



191	Cataract Surgery 20/40 VA	-eCQM update: surgeries performed Jan 1 -Sept 30 ( <b>including those on Sept 30</b> ) are included in the measure. This was the original intent of the measure, so this is just a minor revision in-line with measure intent.
N/A	Acute Posterior Vitreous Detachment Appropriate Examination and Follow-up	-Proposed new MIPS measure.
N/A	Acute Posterior Vitreous Detachment and Acute Vitreous Hemorrhage Appropriate Examination and Follow-up	-Proposed new MIPS measure.
N/A	Appropriate Screening and Plan of Care for Elevated IOP Following Intravitreal or Periocular Steroid Therapy	-Proposed new MIPS measure.

## Dermatology

ID	Name	Measure Specific
138	Melanoma: Coordination of Care	-Removal from MIPS because it has reached the end of the topped-out lifecycle.
485	Psoriasis – Improvement in Patient-Reported Itch Severity	-Changed patient age requirement to include patients 8 years and older (down from 18 and older). -Changed requirement to an itch score reduction of 3+ (up from 2+). -Added note that the VRS tool is only for patients 18+.
486	Dermatitis – Improvement in Patient-Reported Itch Severity	-Changed patient age requirement to include patients 8 years and older (down from 18 and older). -Changed requirement to an itch score reduction of 3+ (up from 2+). -Added note that the VRS tool is only for patients 18+.

## General/Other

ID	Name	Measure Specific
1	Diabetes HbA1C	-MIPS CQM and Claims denominator exclusion added: Donepezil-memantine to the list of dementia medication exclusions.
112	Breast Cancer Screening	-Removal from MIPS because CMS is proposing a new, more comprehensive measure: Preventive Care and Wellness (composite).
113	Colorectal Cancer Screening	-Removal from MIPS because CMS is proposing a new, more comprehensive measure: Preventive Care and Wellness (composite).
128	BMI Screening	-Removal from MIPS because CMS is proposing a new, more comprehensive measure: Preventive Care and Wellness (composite).



134	Screening for Depression and Follow-up Plan	-Removed diagnosis for depression from denominator exclusion so that patients with a previous or inactive diagnosis of depression continue to be screened for reoccurrence.
226	Tobacco Use	-Screening and intervention would now include all patients aged 12 years and older (formerly 18 and older). -Data completeness calculation changed: Will now use criteria 1 (includes all patients who were screened for tobacco use). -Performance rate will still be based on criteria 2 (all patients identified as a tobacco user who received cessation intervention).
236	Controlling High BP	-Added clarification: BP readings taken by a clinician or an automated blood pressure monitor or device are now acceptable as long as the clinician confirms the device or monitor is reliable. -MIPS CQM and Claims denominator exclusion added: Donepezil-memantine to the list of dementia medication exclusions. -eCQM clarification: the encounter must occur during the performance period.
238	Use of High-Risk Meds	<i>MIPS CQM High Risk Medications list modified:</i> -Medications added to <i>Criteria 1 in High-Risk Medications with Average Daily Dose Criteria</i> : Alpha agonists (central), Cardiovascular (other), Tertiary tricyclic antidepressants. -Medications added to <i>Criteria 2</i> : Aripiprazole lauroxil (antipsychotics) -Any medication previously specified as “short acting” or “immediate release” now specifies “(excluding extended release)”. -Medications removed: Nitrofurantoin microcrystals and Doxepin hydrochloride.  -eCQM modification: Drugs ordered on the same day, but meant to start on different days, now count for Rate 2.
402	Tobacco Use and Help with Quitting Among Adolescents	-Removal from MIPS because it is considered duplicative of measure 226: Tobacco Use: Screening and Intervention.
487	Screening for Social Drivers of Health	-Added denominator exception: Patient reason for not screening for the measure’s listed social drivers of health (e.g., patient declined or other patient reasons).
493	Adult Immunization Status	-Remove denominator exclusions for all submission criteria for patients receiving active chemotherapy, who have a bone marrow transplant, or history of immunocompromising conditions as these are not contraindicators for the vaccines. -Add a denominator exception if there is a system reason that the second dose of the zoster vaccine could not be administered in the performance period because of the minimum interval requirement between doses.
N/A	Preventive Care and Wellness (composite)	-Proposed new MIPS measure. Evaluates: influenza and pneumococcal immunizations, mammograms, colorectal cancer screening, BMI screening, tobacco use screening, and high blood pressure screening.